Cohen, Roger B.

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology

Thyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatment

Cited by 550

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 325

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 237

Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

Infante, J. R., Dees, E. C., Olszanski, A. J., Dhuria, S. V., Sen, S., Cameron, S., & Cohen, R. B. (2014) · Journal of Clinical Oncology

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 210

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Sun, L., Hsu, M., Cohen, R. B., Langer, C. J., Mamtani, R., & Aggarwal, C. (2021) · JAMA Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 87

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non–Small-Cell Lung Cancer

Bange, E., Marmarelis, M. E., Hwang, W.-T., Yang, Y.-X., Thompson, J. C., Rosenbaum, J., Bauml, J. M., Ciunci, C., Alley, E. W., Cohen, R. B., et al. (2019) · JCO Precision Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 74

Unsupervised exercise in survivors of human papillomavirus related head and neck cancer: how many can go it alone?

Bauml, J., Kim, J., Zhang, X., Aggarwal, C., Cohen, R. B., & Schmitz, K. (2017) · Journal of Cancer Survivorship

Cancer survivorship and careHead and Neck Cancer Studies

Cited by 10

Abstract LB-407: Down-modulation of mRNA by EZN-2968, an hypoxia-inducible factor-1α (HIF-1α) mRNA antagonist, administered in adult patients with advanced solid tumors

Cohen, R. B., Olszanski, A., Figueroa, J., Hurwitz, H., Lokiec, F. M., Rezaï, K., Berkowitz, N., & Buchbinder, A. (2011) · Cancer Research

Cancer, Hypoxia, and MetabolismRNA Interference and Gene Delivery

Cited by 1